Ocuphire Pharma Investor Presentation Deck

Ocuphire Overview A Late-Stage Clinical Ophthalmic Biotech (Nasdaq Symbol: OCUP) Nyxol® APX3330 3 Presbyopia U.S. Prevalence: ~128M 0. 4 % Positive Phase 2 Top-line Data 2Q21 Advance Two Phase 3 in 2022 Phase 2 Recruiting Phase 2 Top-Line Data in 2022 Night Vision Disturbances U.S. Prevalence: ~16M adults Phase 3 Recruiting Phase 3 Top-Line Data early 2022 Diabetic Retinopathy U.S. Prevalence: ~ 7M Reversal of Mydriasis ~100M pupil dilations per year in U.S. Positive Phase 3 Top-Line Data 1Q21 2nd Phase 3 Planned 2H21 2nd Phase 3 Top-Line Data early 2022 NDA Submission Late 2022 Diabetic Macular Edema U.S. Prevalence: ~750K Ocuphire PHARMA

View entire presentation